ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
127.492,49
1,22%
S&P 500
5.459,10
1,11%
US Dollar vs BRL
5,6561
0,00%
Bitcoin
67.893,65
-0,03%
Brent Oil
79,745
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. AbbVie Inc (ABBV)

  7. AbbVie Inc (ABBV) Notícias

ABBV

AbbVie (ABBV)

AbbVie Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:ABBV
DataHoraFonteTítuloCódigoCompanhia
26/07/202403:00PR Newswire (US)AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisNYSE:ABBVAbbVie Inc
25/07/202408:41Edgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
25/07/202408:36PR Newswire (US)AbbVie Reports Second-Quarter 2024 Financial ResultsNYSE:ABBVAbbVie Inc
25/07/202407:21IH Market NewsU.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire ExpectationsNYSE:ABBVAbbVie Inc
23/07/202408:02PR Newswire (Canada)AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug AgencyNYSE:ABBVAbbVie Inc
23/07/202408:02PR Newswire (Canada)L'Agence des médicaments du Canada octroie à AbbVie sa toute première recommandation de remboursement à durée limitée pour EPKINLY (MC)NYSE:ABBVAbbVie Inc
12/07/202409:30PR Newswire (US)AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell ArteritisNYSE:ABBVAbbVie Inc
10/07/202409:00PR Newswire (US)AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific OfficerNYSE:ABBVAbbVie Inc
05/07/202409:13IH Market NewsTesla Listed for China’s Government Vehicles; Macy’s Acquisition Offer Raised, and More NewsNYSE:ABBVAbbVie Inc
02/07/202409:00PR Newswire (US)AbbVie to Host Second-Quarter 2024 Earnings Conference CallNYSE:ABBVAbbVie Inc
01/07/202409:00PR Newswire (US)Robert A. Michael Assumes Role as AbbVie Chief Executive OfficerNYSE:ABBVAbbVie Inc
28/06/202403:00PR Newswire (US)AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaNYSE:ABBVAbbVie Inc
27/06/202410:26PR Newswire (US)AbbVie Acquires Celsius TherapeuticsNYSE:ABBVAbbVie Inc
27/06/202409:30PR Newswire (US)Introducing Allē Payment Plans, Powered by CherryNYSE:ABBVAbbVie Inc
26/06/202420:03PR Newswire (US)U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular LymphomaNYSE:ABBVAbbVie Inc
25/06/202409:15PR Newswire (US)AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)NYSE:ABBVAbbVie Inc
21/06/202409:00PR Newswire (US)AbbVie Declares Quarterly DividendNYSE:ABBVAbbVie Inc
20/06/202409:00PR Newswire (US)AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of DirectorsNYSE:ABBVAbbVie Inc
18/06/202419:18PR Newswire (US)U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel DiseaseNYSE:ABBVAbbVie Inc
14/06/202417:08PR Newswire (US)AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" OfferNYSE:ABBVAbbVie Inc
13/06/202408:59PR Newswire (US)AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel DiseaseNYSE:ABBVAbbVie Inc
11/06/202409:00PR Newswire (US)BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant RecipientsNYSE:ABBVAbbVie Inc
06/06/202409:45PR Newswire (US)AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian CancerNYSE:ABBVAbbVie Inc
06/06/202409:30PR Newswire (US)SkinMedica® Celebrates 25 Years of Empowering Radiant SkinNYSE:ABBVAbbVie Inc
06/06/202409:00PR Newswire (US)AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their CareersNYSE:ABBVAbbVie Inc
05/06/202410:00PR Newswire (US)AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383NYSE:ABBVAbbVie Inc
04/06/202409:30PR Newswire (US)RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic ArthritisNYSE:ABBVAbbVie Inc
04/06/202409:05PR Newswire (US)Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50NYSE:ABBVAbbVie Inc
03/06/202409:30PR Newswire (US)AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:ABBVAbbVie Inc
31/05/202417:05Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:ABBVAbbVie Inc
 Apresentando as notícias mais relevantes sobre:NYSE:ABBV

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
COGN3
COGNA ON
BOV
USIM5
USIMINAS PNA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados